NKT細胞免疫系を標的にした悪性腫瘍に対する免疫細胞治療(<特集>細胞治療とアフェレシス)

概要

論文の詳細を見る
Human Vα24 natural killer T (NKT) cells bearing an invariant Vα24JaQ antigen receptor, the counterpart of murine Vα14 NKT cells, are activated by a specific ligand, αGalactosylceramide (αGalCer; KRN 7000) in a CD1d dependent manner. Previous findings showed that αGalCer-pulsed dendritic cells (DCs) exerted a strong antitumor activity in the mouse tumor metastatic models and intravenous administration of αGalCer-pulsed DCs led to Vα14 NKT cell expansion in the lung. With these results, we performed a phase I dose escalation study of αGalCer-pulsed DCs treatment in patients with lung cancer. Patients with advanced non-small cell lung cancer or recurrent lung cancer received intravenous injection of αGalCer pulsed dendritic cell immune therapy to test the safety, feasibility, and clinical response. Immunomonitoring was also performed in all completed cases. Eleven patients were enrolled in this study. No severe adverse events occurred during this study in any patient. Peripheral blood Vα24 NKT cells dramatically increased after the first and second injection of α GalCer pulsed DCs in one patient of level 3. Clinical trial of α GalCer-pulsed DCs administration is well tolerated and this therapy has been carried out safely. To obtain more conclusive findings about immune responses and antitumor responses, phase I-II study with greater numbers of patients is ongoing.
日本アフェレシス学会の論文
2007-05-31